{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:58:13Z","timestamp":1767034693902},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Science Foundation of Tianjin","award":["09KZ73"],"award-info":[{"award-number":["09KZ73"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12094-017-1664-8","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T13:05:10Z","timestamp":1493125510000},"page":"1260-1267","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients"],"prefix":"10.1007","volume":"19","author":[{"given":"Q.-L","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.-X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"issue":"1","key":"1664_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1664_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R Angelis De","year":"2014","unstructured":"De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE\u00a0\u2212\u00a05-a population-based study. Lancet Oncol. 2014;15(1):23\u201334.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1664_CR3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","volume":"68","author":"RC Bast Jr","year":"1981","unstructured":"Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331\u20137.","journal-title":"J Clin Invest"},{"issue":"1","key":"1664_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0090-8258(90)90394-Z","volume":"39","author":"B Tholander","year":"1990","unstructured":"Tholander B, Taube A, Lindgren A, Sj\u00f6berg O, Stendahl U, Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol. 1990;39(1):26\u201333.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1664_CR5","doi-asserted-by":"crossref","first-page":"15636","DOI":"10.3390\/ijms140815636","volume":"14","author":"R Saldova","year":"2013","unstructured":"Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM. Exploring the glycosylation of serum CA125. Int J Mol Sci. 2013;14(8):15636\u201354.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1664_CR6","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","volume":"57","author":"JM Escudero","year":"2011","unstructured":"Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57(11):1534\u201344.","journal-title":"Clin Chem"},{"issue":"3","key":"1664_CR7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ygyno.2012.09.003","volume":"127","author":"D Trudel","year":"2012","unstructured":"Trudel D, T\u00eatu B, Gr\u00e9goire J, Plante M, Renaud MC, Bachvarov D, et al. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol. 2012;127(3):511\u20135.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1664_CR8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(06)70579-4","volume":"7","author":"D Bouchard","year":"2006","unstructured":"Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with wheyacidic-protein motifs and cancer. Lancet Oncol. 2006;7(2):167\u201374.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1664_CR9","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.ajog.2011.12.029","volume":"206","author":"RG Moore","year":"2012","unstructured":"Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA 125 in women with benign gynecological disorders. Am J Obstet Gynecol. 2012;206(4):351.e1\u20138.","journal-title":"Am J Obstet Gynecol."},{"issue":"7","key":"1664_CR10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/IGC.0b013e318263efa2","volume":"22","author":"L Wu","year":"2012","unstructured":"Wu L, Dai ZY, Qian YH, Shi Y, Liu FJ, Yang C. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer. 2012;22(7):1106\u201312.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"1664_CR11","doi-asserted-by":"crossref","first-page":"358.e1","DOI":"10.1016\/j.ajog.2011.05.017","volume":"205","author":"K Holcomb","year":"2011","unstructured":"Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011;205(4):358.e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1664_CR12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ygyno.2012.03.011","volume":"125","author":"M Hallamaa","year":"2012","unstructured":"Hallamaa M, Suvitie P, Huhtinen K, Matom\u00e4ki J, Poutanen M, Perheentupa A. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecol Oncol. 2012;125(3):667\u201372.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1664_CR13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","volume":"112","author":"RG Moore","year":"2009","unstructured":"Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40\u20136.","journal-title":"Gynecol Oncol"},{"issue":"2 Pt 1","key":"1664_CR14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","volume":"118","author":"RG Moore","year":"2011","unstructured":"Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118(2 Pt 1):280\u20138.","journal-title":"Obstet Gynecol"},{"key":"1664_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cca.2014.11.015","volume":"440","author":"AM Chudecka-G\u0142az","year":"2015","unstructured":"Chudecka-G\u0142az AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta. 2015;440:143\u201351.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1664_CR16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IGC.0b013e318234f852","volume":"22","author":"S Kadija","year":"2012","unstructured":"Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 2012;22(2):238\u201344.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1664_CR17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ygyno.2015.09.010","volume":"139","author":"E Lokich","year":"2015","unstructured":"Lokich E, Palisoul M, Romano N, Craig Miller M, Robison K, Stuckey A, et al. Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass. Gynecol Oncol. 2015;139(2):248\u201352.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1664_CR18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s13277-014-2738-7","volume":"36","author":"H Fujiwara","year":"2015","unstructured":"Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumour Biol. 2015;36(2):1045\u201353.","journal-title":"Tumour Biol"},{"issue":"2","key":"1664_CR19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2016.01.016","volume":"141","author":"C Romagnolo","year":"2016","unstructured":"Romagnolo C, Leon AE, Fabricio AS, Taborelli M, Polesel J, Del Pup L, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecol Oncol. 2016;141(2):303\u201311.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1664_CR20","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65(6):2162\u20139.","journal-title":"Cancer Res"},{"issue":"19","key":"1664_CR21","first-page":"3133","volume":"124","author":"SL Zou","year":"2011","unstructured":"Zou SL, Chang XH, Ye X, Cheng HY, Cheng YX, Tang ZJ, et al. Effect of human epididymis protein 4 gene silencing on the malignant phenotype in ovarian cancer. Chin Med J. 2011;124(19):3133\u201340.","journal-title":"Chin Med J"},{"issue":"3","key":"1664_CR22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PAT.0b013e32835f2264","volume":"45","author":"D Lim","year":"2013","unstructured":"Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013;45(3):229\u201342.","journal-title":"Pathology"},{"issue":"3","key":"1664_CR23","doi-asserted-by":"crossref","first-page":"257.e1","DOI":"10.1016\/j.ajog.2013.11.022","volume":"210","author":"LL Holman","year":"2014","unstructured":"Holman LL, Lu KH, Bast RC, Hernandez MA, Bodurka DC, Skates S, et al. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014;210(3):257.e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1664_CR24","doi-asserted-by":"crossref","first-page":"349.e1","DOI":"10.1016\/j.ajog.2011.12.028","volume":"206","author":"RG Moore","year":"2012","unstructured":"Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206(4):349.e1\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"1664_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0201-z","author":"Y Tian","year":"2015","unstructured":"Tian Y, Wang C, Cheng L, Zhang A, Liu W, Guo L, et al. Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women. J Ovarian Res. 2015;. doi:\n                        10.1186\/s13048-015-0201-z\n                        \n                    .","journal-title":"J Ovarian Res"},{"key":"1664_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cca.2014.07.040","volume":"438","author":"J Kappelmayer","year":"2015","unstructured":"Kappelmayer J, Antal-Szalm\u00e1s P, Nagy B Jr. Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders. Clin Chim Acta. 2015;438:35\u201342.","journal-title":"Clin Chim Acta"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-017-1664-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1664-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T09:42:23Z","timestamp":1505382143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-017-1664-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1664"],"URL":"https:\/\/doi.org\/10.1007\/s12094-017-1664-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}